Get to know Jeffrey: A teacher’s perspective on living life to the fullest with Parkinson’s

Image of Jeffrey, real CREXONT patient.

Jeffrey has always approached life with a good sense of humor and an unwavering dedication to helping others in his community. As a longtime chiropractor and professor, he’s passionate about connecting with students, encouraging empathy and compassion and reminding them that every patient is more than just a diagnosis.

“I tell my students that you’re not treating a disease, you’re treating a person, trying to live their life. That perspective matters.”

Jeffrey’s story took a personal turn in his early 60s when he began experiencing unexplained tremors and issues with coordination and non-motor signs. At first, he didn’t acknowledge or recognize the signs. Like many people and some doctors unfamiliar with Parkinson’s disease (PD), they couldn’t put it all together.

But after a series of tests and visits with his neurologist, he finally received a diagnosis: Parkinson’s disease. “I went through all the stages of grief. Anger. Denial. I remember thinking, ‘Why me?’” Jeffrey recalls. “But after some time, I got into the mindset of, ‘Put one foot in front of the other and just live.’”

As a self-described perfectionist, Jeffrey noticed how PD started impacting his day-to-day life, particularly his energy and mood. Teaching, which was once a joy for him, became a struggle. He felt he wasn’t himself with his students. That’s when he knew something had to change.

After exploring a few different treatment options, Jeffrey and his doctor decided it was time to try a new approach. In February, with support from his care team to navigate access, he began taking CREXONT® (carbidopa and levodopa) extended-release capsules, 70 mg/280 mg carbidopa/levodopa three times per day. Within weeks, he noticed changes in how he moved around his home, especially his walking and arm swing. “I don’t want people looking at me and seeing someone who’s sick. I don’t want pity. I just want to feel like myself.” While every patient’s journey is unique, for Jeffrey, consistency in care and treatment has been key.

Image of Stuart, a real patient taking CREXONT, with his bowling team.

Today, as an avid bowler, he competes several times a week with a group of friends to socialize and hone his skills. And he continues to lean on the love and support of his wife of 35 years, Yvonne. “I’m fortunate to have her by my side. I don’t know if I could do it alone,” he says.

Jeffrey knows that Parkinson’s isn’t something you choose, but how you respond to it is. His story is one of self-awareness, strength, and a desire to keep doing the things that make him feel most like himself. “I found something that helps me feel more like my old self again,” he says. “That matters. I just want to live my life.”

When asked why he wanted to share his story, Jeffrey shared “I would hate to go back and start all over. This works for me, and that means everything.”

Jeffrey’s experience with CREXONT is his own and may not reflect the experience of every patient. For some patients, CREXONT may cause falling asleep during daily activities. Side effects may include nausea and anxiety. Individual results will vary. Talk to your patients to see if CREXONT is right for them. Only an HCP should assess each patient’s condition and advise them on treatment options.


IMPORTANT SAFETY INFORMATION

Indications and Usage

CREXONT® (carbidopa and levodopa) extended-release capsules for oral use is indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults.

Dosage and Administration

  • Levodopa-naïve patients: Starting dose is 35 mg carbidopa/140 mg levodopa taken orally twice daily for the first three days; thereafter, dosage may be increased gradually as needed
  • For patients converting to CREXONT from immediate-release carbidopa/levodopa, dosages are not substitutable on a 1:1 basis. See full prescribing information Section 2.2 for instructions
  • For patients converting from Rytary® (carbidopa and levodopa) extended-release capsules, initiate CREXONT on an approximately 1:1 mg basis using the levodopa component for conversion
  • CREXONT may be taken up to four times daily. The maximum recommended daily dosage is 525 mg carbidopa/2100 mg levodopa
  • CREXONT may be taken with or without food. Capsules should not be chewed, divided or crushed
  • CREXONT should not be taken with alcohol

Contraindications

Nonselective MAO inhibitors.

Warnings and Precautions

  • CREXONT may cause falling asleep during activities of daily living, somnolence or dizziness. Patients should avoid activities that require alertness such as driving and operating machinery until they know how CREXONT affects them
  • It is important to avoid sudden discontinuation or rapid dose reduction to reduce the risk of withdrawal symptoms such as high fever or confusion. Patients who are discontinuing CREXONT should taper off with healthcare provider guidance
  • Consider dose reductions or stopping CREXONT in patients with hallucinations or impulse control disorders (e.g., gambling, sexual urges, or uncontrolled spending)
  • Consider dose reduction in patients with dyskinesia
  • Patients with a major psychotic disorder should not be treated with CREXONT
  • Monitor patients with a history of cardiovascular disease for cardiac function
  • Monitor patients with a history of peptic ulcer for upper GI hemorrhage
  • Monitor patients with glaucoma for increased intraocular pressure

Adverse Reactions

The most common adverse reactions (incidence ≥ 3% and greater than immediate-release CD/LD) are nausea and anxiety.

Drug Interactions

Iron salts and dopamine D2 antagonists, including metoclopramide, may reduce the effectiveness of CREXONT.

Use in Specific Populations

Pregnancy: Based on animal data, CREXONT may cause fetal harm. There are no adequate data on the developmental risk associated with the use of CREXONT in pregnant women.
Breastfeeding: The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for CREXONT.
Geriatric patients: There were no differences in safety outcomes between patients less than 65 years of age, 65-75 years of age, or 75 years and older.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Specialty, a division of Amneal Pharmaceuticals, LLC at 1‑877‑835‑5472 or the FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for CREXONT.

Content is for guidance only. Please use clinical judgment when prescribing CREXONT. Dosage is individualized for each patient.